### **Supplementary information**

# Design, synthesis, and cell-based in vitro assay of deoxyinosine-mixed SATE-dCDN prodrugs that activate all common STING variants

Zhiqiang Xie <sup>a</sup>, Yuchen Yang <sup>a</sup>, Dejun Ma <sup>a</sup>, Zhen Xi \*, <sup>a, b, c, d</sup>

<sup>a.</sup> State key Laboratory of Elemento-organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China

<sup>b.</sup> National Pesticide Engineering Research Centre (Tianjin 300071)

<sup>c.</sup> Haihe Laboratory of Sustainable Chemical Transformations, Tianjin 300192 (China)

<sup>d.</sup> Collaborative Innovation Centre of Chemical Science and Engineering (Tianjin), Tianjin 300071, China

\* Corresponding author. *E-mail address:* <u>zhenxi@nankai.edu.cn</u>. (Z. Xi)

### **Table of Contents**

| Title   | Page       |
|---|------------|
| 1. Serum stability  | S2         |
| 2. Intracellular uptake and efflux of SATE-dCDN prodrugs  | <b>S</b> 3 |
| 3. Activities of deoxyinosine-mixed dCDN prodrugs and CDNs  | <b>S</b> 3 |
| 4. Cell viability   | <b>S</b> 4 |
| 5. Activity against five hSTING variants  | S5         |
| 6. RT-qPCR primers of target genes and the internal control gene                                      | S5         |
| 7. Relative quantification of phospho-STING, phospho-TBK1, phospho-IRF3                               | <b>S</b> 6 |
| 8. Chemical characterization of <sup>1</sup> H, <sup>13</sup> C, <sup>31</sup> P NMR and HPLC spectra | S7-S53     |
| 9. Raw Images of western blots  | S54-S60    |

### 1. Serum stability



Fig. S1 Deoxyinosine-mixed SATE-dCDN prodrugs retained the high serum stability. The serum stability analysis of prodrugs was determined in 20% FBS. Each compound (100  $\mu$ M) was incubated in 20% FBS at 37°C. At various time (0 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, 120 h), aliquots of the reaction mixture were analyzed with HPLC at 254 nm. The % remaining of test compounds after incubation in serum was calculated.

| Compounds   | $T_{1/2}$ (h) |
|-------------|---------------|
| 13d         | 105           |
| <b>13</b> e | 77            |
| 13f         | 86            |
| 14a         | 73            |
| 14b         | 114           |
| 14c         | 70            |
| 15          | 72            |
| 2',3'-cGAMP | 31            |
| ADU-S100    | 67            |

Table S1. The half-life period of deoxyinosine-mixed dCDN prodrugs and CDNs

### 2.Intracellular uptake and efflux of SATE-dCDN prodrugs



**Fig. S2**. Uptake and efflux of SATE-dCDN prodrugs. (A) (B) THP-1 cells were treated with 10  $\mu$ M prodrug **15** or 100  $\mu$ M parent dCDN 3',3'-c-di-dAMP for the indicated period of time, and intracellular levels of the metabolites were determined in cellular extracts.

### 3. Activities of deoxyinosine-mixed dCDN prodrugs and CDNs



**Fig. S3**. Activities of deoxyinosine-mixed dCDN prodrugs and CDNs. The EC<sub>50</sub> values of **14a** (A), **13d** (B), **14b** (c), **13e** (d), 2',3'-cGAMP (E) and ADU-S100 (F) were also assessed in THP1-Lucia cells.



Fig. S4. The comparison of  $E_{max}$ . The  $E_{max}$  values of 13d-13e, 14a-14c, 2',3'-cGAMP and ADU-S100 were also assessed in THP1-Lucia cells.



4. Cell viability

**Fig. S5.** Cell viability of THP-1 and HEK293T cells stimulated by inosine-mixed dCDN prodrugs and CDNs. (A)  $5 \times 10^3$  HEK293T cells or (B) THP-1 cells were seeded in 96-well plates. Cells were stimulated with inosine-mixed dCDN prodrugs (10  $\mu$ M), 2',3'-cGAMP (100  $\mu$ M) and ADU-S100 (10  $\mu$ M) for 24 h. Then Cell Counting Kit-8 (CCK8) (US EVERBRIGHT, c6005) was used to quantitatively assess cell viability through the OD value at 450 nm. Data were presented as mean  $\pm$  SD, n = 3.

### 5. Activity against five hSTING variants



Fig. S6. The luciferase-based bioactivity evaluation of 14a, 3',3'-c-di-dIdAMP (6), SATE-3',3'-c-di-dAMP (15) against five hSTING variants. HEK293T cells were cotransfected with IFN- $\beta$ -luciferase reporter plasmids and the test plasmids expressing (A) hSTING-WT, (B) hSTING-HAQ, (C) hSTING-AQ, (D) hSTING-R232H, and (E) hSTING-R293Q. After 24 h, cells were further stimulated for 24 h in the presence of tested compound (50  $\mu$ M). The cells were lysed for luciferase assay. Data were presented as mean  $\pm$  SD, n=3.

| Primer name | Sequence (5'-3')       |  |
|-------------|------------------------|--|
| IFN-β-F     | AACAAGTGTCTCCTCCAAAT   |  |
| IFN-β-R     | TCTCCTCAGGGATGTCAAAG   |  |
| CXCL10-F    | CATTCTGATTTGCTGCCTTAT  |  |
| CXCL10-R    | TTGATGGCCTTCGATTCTGG   |  |
| IL-6-F      | AGACAGCCACTCACCTCTTCAG |  |
| IL-6-R      | TTCTGCCAGTGCCTCTTTGCTG |  |
| TNF-α-F     | TGAAAGCATGATCCGGGACG   |  |
| TNF-α-R     | AGGCAGAAGAGCGTGGTGGC   |  |

**6. RT-qPCR primers of target genes and the internal control gene Table S2. RT-qPCR primers of target genes and the internal control gene** 

# 40 phospho-STING phospho-TBK1 phospho-IRF3 20 10 0 2',3'-cGAMP ADU-S100 control 14a

# 7. Relative quantification of phospho-STING, phospho-TBK1, phospho-IRF3

**Fig. S7.** Relative quantification of phospho-STING, phospho-TBK1, phospho-IRF3. Prodrug **14a** (10  $\mu$ M), 2',3'-cGAMP (100  $\mu$ M) and ADU-S100 (10  $\mu$ M) were used to treat THP1 cells for 4 h, and the levels of total STING, phospho-STING, total TBK1, phospho-TBK1, total IRF3, phospho-IRF3, and  $\beta$ -actin were assessed by Western blotting.

### 8. Chemical characterization of <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR and HPLC spectra



<sup>1</sup>H, <sup>13</sup>C spectra of 8:

### <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR spectra of **9a:**

### 





### <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **9b**:

### $\begin{array}{c} 7.821\\ 7.7321\\ 7.7328\\$



### 205.627 205.627 205.622 205.622 205.627 170.139 155.657 155



### 8,8191 8,8177 8,8177 8,8177 8,8177 8,8177 8,8177 8,8177 8,8177 1,7334 1,77314



### 205.561 205.561 205.561 205.561 205.516 205.516 205.501 205.501 205.501 205.501 205.501 205.501 200.55 20





# <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **9d**:











130 110 90 80 70 60 50 40 30 20 10 0 -20 -40 -60 -80 -100 -120 -140 fl (ppm)





<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **9f:** 

### 10.033 10.033 10.033 10.033 17.258 17.512













<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **11a:** 





### 





<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **11c:** 

### 9.387 9.338 8.308 7.387 7.387 7.387 7.259 7.7240 7.7240 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.972 6.191 6.176 6.191 6.176 6.176 6.172 6.973 6.972 6.973 6.191 6.176 6.176 6.172 6.973 6.973 6.973 6.973 6.973 6.191 6.176 7.223 7.3778 7.3.0787 7.3.07877 7.3.07877777777777777

























130 110 90 80 70 60 50 40 30 20 10 0 -20 -40 -60 -80 -100 -120 -140 fl (ppm)





### <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **12a:**







-205.654

### 8.164 5.53419 5.54419 5.544







230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm)







### 205.707 205.707 205.707 161.258 161.258 161.258 161.258 161.258 161.258 161.258 161.258 161.256 161.256 161.256 161.256 161.257 165.557 112.2313 112.2313 112.2313 112.2358 112.2358 112.2358 112.2358 112.2358 111.6.764 112.239 112.239 113.725



S32



<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **12e:** 











230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)



### <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR of **13a:**







### 



### 205.730 1170.524 1155.329 1155.643 1155.643 1155.3543 1155.3543 1155.3543 1155.3543 1155.3543 1155.3543 1155.3543 1155.3543 1155.3547 1155.3547 1155.3547 1155.3547 1155.3547 1155.3547 1155.3547 1155.3547 1152.3547 1122.35467 1122.3547 1122.35467 1122.32467 1122.35467 1222.35467



### -0.969 -1.636 -3.873 -3.975 -4.055 -4.183 -4.552





S40







Wavelength = 254 nm

| Peak | RetTime | Туре | Width  | Area       | Height    | Area    |
|------|---------|------|--------|------------|-----------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]     | %       |
|      |         |      |        |            |           |         |
| 1    | 5.573   | MM   | 0.0717 | 1014.18024 | 235.73274 | 96.3637 |
| 2    | 5.976   | MM   | 0.0750 | 20.77244   | 4.61885   | 1.9737  |
| 3    | 6.145   | MM   | 0.0537 | 7.69655    | 2.38733   | 0.7313  |
| 4    | 7.039   | MM   | 0.0414 | 9.80099    | 3.94245   | 0.9313  |

### 8.351 8.4087 8.4087 8.4087 8.4087 8.4087 8.4087 8.4087 8.4087 8.4175 8.4175 8.4175 8.4175 8.4135 8.4





| Peak | RetTime | Туре | Width  | Area       | Height    | Area    |
|------|---------|------|--------|------------|-----------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]     | %       |
|      |         |      |        |            |           |         |
| 1    | 5.123   | MM   | 0.0835 | 125.89102  | 25.13762  | 2.6307  |
| 2    | 6.687   | MM   | 0.1344 | 4659.58008 | 577.70349 | 97.3693 |

8.228 8.228 5.5496 5.5437 7.7025 5.5496 5.5437 7.7025 5.5486 5.5487 5.5487 5.5487 5.5487 5.5487 5.5487 5.5385 5.5487 5.5385 5.54855 5.5485 5.5485 5.5485 5.5485 5.5485 5.5485 5.5485 5.5485





| Peak | RetTime | Туре | Width  | Area       | Height    | Area    |
|------|---------|------|--------|------------|-----------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]     | %       |
|      |         |      |        |            |           |         |
| 1    | 1.308   | MM   | 0.0330 | 6.46085    | 3.25869   | 0.6316  |
| 2    | 5.905   | MM   | 0.0695 | 1007.19232 | 241.39569 | 98.4538 |
| 3    | 6.066   | MM   | 0.0353 | 9.35646    | 4.42184   | 0.9146  |





Wavelength = 254 nm

| Peak | RetTime | Туре | Width  | Area       | Height    | Area    |
|------|---------|------|--------|------------|-----------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]     | %       |
|      |         |      |        |            |           |         |
| 1    | 1.963   | MM   | 0.0630 | 15.87361   | 4.19902   | 1.1732  |
| 2    | 6.370   | MM   | 0.0983 | 1308.21338 | 221.85370 | 96.6845 |
| 3    | 8.146   | MM   | 0.0730 | 28.98730   | 6.61780   | 2.1423  |



S49



| Peak | RetTime | Туре | Width  | Area       | Height    | Area    |
|------|---------|------|--------|------------|-----------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]     | %       |
|      |         |      |        |            |           |         |
| 1    | 5.091   | MM   | 0.0398 | 56.45222   | 23.61695  | 3.7679  |
| 2    | 6.518   | MM   | 0.0985 | 1441.80322 | 244.03915 | 96.2321 |

<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR and HPLC spectra of **14c:** 







Wavelength = 254 nm

Peak RetTime Type Height Width Area Area [mAU\*s] [min] [min] [mAU] % # 0.1029 1414.92310 1 6.116 MM 229.15054 96.5644 14.21182 2 6.651 MM 0.0590 50.34100 3.4356



Wavelength = 254 nm

| Peak | RetTime | Туре | Width  | Area       | Height     | Area    |
|------|---------|------|--------|------------|------------|---------|
| #    | [min]   |      | [min]  | [mAU*s]    | [mAU]      | %       |
|      |         |      |        |            |            |         |
| 1    | 2.011   | MM   | 0.0682 | 5070.32373 | 1238.31140 | 97.8230 |
| 2    | 8.138   | ММ Т | 0.0821 | 89.43742   | 18.16607   | 1.7255  |
| 3    | 8.466   | MM   | 0.0636 | 23.40262   | 6.13035    | 0.4515  |

HPLC spectra of ADU-S100:



Wavelength = 254 nm

| Peak | RetTime | Туре | Width  | Area      | Height     | Area    |
|------|---------|------|--------|-----------|------------|---------|
| #    | [min]   |      | [min]  | [mAU*s]   | [mAU]      | %       |
|      |         |      |        |           |            |         |
| 1    | 1.953   | MM   | 0.0804 | 8.04880   | 1.66835    | 1.1890  |
| 2    | 4.432   | MM   | 0.1575 | 658.17188 | 69.62640   | 97.2300 |
| 3    | 5.240   | MM   | 0.1249 | 5.06311   | 6.75574e-1 | 0.7480  |
| 4    | 5.513   | MM   | 0.1258 | 5.63901   | 7.46921e-1 | 0.8330  |

**Raw Images of western blots:** 

pSTING



# Total STING



# pTBK1



# Total TBK1





# Total IRF3



# β-actin

